© 2024 © 2020 Genprex Inc. All Rights Reserved.
Review our latest corporate presentation with an overview of company highlights, recent milestones and clinical updates.
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update
This study suggests the mechanism by which REQORSA treatment affects immune and other non-cancerous cells that leads to increased immune response against tumors. The study further suggested that REQORSA may play an important role as a cancer treatment to target and disrupt the metabolism of cancer cells, leading to a decrease in the rate of glycolysis.
In the study, lung metastases in humanized mice were treated through I.V. injection of NPRL2 nanoparticles, made with the ONCOPREX Delivery System, with or without pembrolizumab. The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect.
Researchers reported that REQORSA induced apoptosis in alectinib resistant EML4-ALK positive non-small cell lung cancer (NSCLC) cell lines.
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®
Preclinical results show that REQORSA® in combination with a checkpoint inhibitor has anti-tumor activity in a humanized mouse model of small cell lung cancer (SCLC)
The abstract reports NPRL2 gene therapy induces effective anti-tumor activity in non-small cell lung cancer pembrolizumab resistant tumors in a humanized mouse model and provides preclinical validation of the ONCOPREX® Nanoparticle Delivery System with a second tumor suppressor gene
Data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) on February 25, 2023 in Berlin, Germany.
A bibliography of selected publications describing the PDX1 and MAFA genes.
The poster presents positive preclinical data for REQORSA in combination with Tagrisso®, demonstrating synergistic antitumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.
The study found TUSC2 may be a novel target and biomarker for thyroid cancer therapy.
The poster demonstrates research and data on the efficacy of novel immunogene combinations for KRAS and LKB1 mutant NSCLC in a humanized mouse model.
The study found that TUSC2 prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options.
The poster presents positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a humanized mouse model.
The poster describes a novel anticancer therapeutic strategy using a new class of rationally designed dual DNA alkylating/HDAC inhibitors combined with nanoparticle-mediated gene therapy targeting the DNA damage/repair pathway in human NSCLC and SCLC cells.
The poster presents data on the synergistic antitumor activity of MK2206 and TUSC2/FUS1-nanoparticle in NSCLC.
We’re passionate about the work we’re doing to fight cancer and diabetes, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.